Opthea Limited (AU:OPT) has released an update.
Opthea Limited, a biopharmaceutical company focused on retinal diseases, is set to engage with investors at two major conferences in November 2024. The company is advancing its lead product, sozinibercept, currently in Phase 3 trials aimed at enhancing vision treatment outcomes. This presents a significant opportunity for investors interested in innovative healthcare solutions.
For further insights into AU:OPT stock, check out TipRanks’ Stock Analysis page.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
